People · Operator
Named in public records as an officer, director or promoter · active 2019–2025 · Biotechnology, Other
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Galvanize Therapeutics, Inc. | — | Biotechnology | Series C | $150.7M | $582.3M | 2025 |
| ShiraTronics, Inc | — | Biotechnology | Series C | $79.1M | $307.5M | 2024 |
| InjectSense, Inc. | — | Other | Series A | $13.9M | $61.9M | 2019 |
Zack Scott at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Zack Scott on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Seth Harrison | 1 | 19 |
| Casey Tansey | 1 | 14 |
| Joyce Erony | 1 | 8 |
| David Lewis | 1 | 7 |
| ANTOINE PAPIERNIK | 1 | 6 |
| David McIntyre | 1 | 5 |
| Mudit Jain | 1 | 4 |
| Brad Vale | 1 | 4 |
| Jonathan Waldstreicher | 1 | 3 |
| Doug Godshall | 1 | 3 |
| Philip H. Oettinger | 1 | 2 |
| Robert Binney | 1 | 2 |
| Lynn Elliott | 1 | 1 |
| Enrique Malaret | 1 | 1 |
| Ariel Cao | 1 | 1 |
| Philip Oettinger | 1 | 1 |
| Steve Anheier | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.